Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-02-28 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
2022年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2022 second extraordinary general meeting of shareholders of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or detailed report content, only the official voting results and meeting summary. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA). The document length is short (1801 characters), consistent with a voting results announcement rather than a full report or presentation.
2022-02-28 Chinese
2022年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of the 2022 second extraordinary general meeting (EGM) of shareholders of a company. It details the legal compliance of the meeting's call, attendance, voting process, and results. It does not contain financial statements or management discussion but focuses on the legality and validity of the shareholder meeting and its resolutions. This type of document is typically classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and procedural compliance of a shareholder meeting.
2022-02-28 Chinese
第四届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the sixth meeting of the fourth Supervisory Board of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, and the voting results on specific proposals related to changes in project implementation locations and use of excess raised funds. The document does not contain financial statements or detailed financial analysis but serves as an official disclosure of board decisions. It is not an annual report, audit report, earnings release, or any form of financial report. It is also not a notice of voting results from a shareholder meeting but rather a supervisory board meeting resolution announcement. Given the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous official company announcements that do not fit other specific categories. The document length is short (1222 characters), and it is a formal announcement rather than a report or presentation.
2022-02-11 Chinese
关于使用部分超募资金投资建设年产1000吨核苷系列食品营养强化剂项目的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of part of its over-raised funds (超募资金) to invest in a specific project: the construction of a production line for nucleoside series food nutrition fortifiers. It details the investment amount, project description, approvals by the board and supervisory committee, independent director opinions, and the need for shareholder approval. The document includes references to regulatory approvals, meeting resolutions, and compliance with stock exchange rules. It is not a financial report, earnings release, or management discussion, but rather a formal disclosure about capital usage and investment plans. This fits the category of a Capital/Financing Update (CAP), as it concerns updates on company fundraising and capital usage. The document length is over 6,000 characters and contains substantive content about the capital investment plan, not just an announcement of a report publication or a regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2022-02-11 Chinese
中天国富证券有限公司关于新乡拓新药业股份有限公司使用部分超募资金投资建设年产1000吨核苷系列食品营养强化剂项目的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company (中天国富证券有限公司) regarding the use of part of the over-raised funds by 新乡拓新药业股份有限公司 for investment in a specific project: the construction of an annual production capacity of 1,000 tons of nucleoside series food nutrition fortifiers. It includes detailed financial figures about the fundraising, the use of funds, project description, necessity, feasibility, economic and social benefits, risk analysis, and approvals by the board, supervisory committee, and independent directors. The document also contains the sponsor's verification opinion and compliance with regulatory requirements. It is a formal, comprehensive report on the use of raised capital funds, including audit and supervisory opinions, which is typical of an Audit Report / Information filing rather than a simple announcement or a general regulatory filing. The length (over 6,000 characters) and the detailed content confirm it is not a brief announcement or certification. Therefore, the document fits best under the Audit Report / Information (AR) category. Q1 2022
2022-02-11 Chinese
关于变更部分募投项目实施地点的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about changing the implementation location of part of its fundraising investment projects. It details the original and new locations, confirms that the use and amount of raised funds remain unchanged, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document references the company's fundraising activities and regulatory approvals but does not contain financial statements or detailed financial data. It is a regulatory announcement about a change related to capital use but not a financial report or earnings release. The document length is short (2492 characters) and it is an announcement of a change related to capital projects, fitting the category of Capital/Financing Update (CAP).
2022-02-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.